This inventor holds 1 USPTO granted patent. Top assignee: Ophidian Pharmaceuticals, Inc.. Active years: 2000.
Company Filing History:
Years Active: 2000
Title: Kirby Johnson - Innovator in TGF-β Pathway Research
Introduction
Kirby Johnson is a notable inventor based in Madison, WI (US). She has made significant contributions to the field of biotechnology, particularly in the study of the TGF-β pathway. Her innovative work has led to the development of valuable compositions and methods that enhance our understanding of this critical biological pathway.
Latest Patents
Kirby Johnson holds 1 patent for her invention titled "Compositions and methods for identifying and testing TGF-β pathway." This invention provides compositions and methods for identifying and testing TGF-β pathway agonists and antagonists. Specifically, it includes compositions comprising Mothers against DPP (MAD) proteins and related Smad polypeptides that exhibit sequence-specific DNA-binding activity. Additionally, the invention introduces novel DNA sequences (SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21) that are bound with high affinity by Drosophila MAD protein. This protein is instrumental in identifying compounds that can enhance or interfere with MAD protein-DNA binding.
Career Highlights
Kirby Johnson is currently associated with Ophidian Pharmaceuticals, Inc., where she continues to advance her research in the field. Her work is pivotal in developing therapeutic strategies that target the TGF-β pathway, which is crucial for various biological processes and disease mechanisms.
Collaborations
Some of her notable coworkers include Jaeseob Kim and Allen Laughon, who contribute to her research endeavors and collaborative projects.
Conclusion
Kirby Johnson's innovative work in the TGF-β pathway research exemplifies her commitment to advancing biotechnology. Her contributions are significant in the quest for new therapeutic approaches, and her patent reflects her expertise and dedication to the field.